Difference between revisions of "ERF for short term PM10 exposure and medication usage by people with asthma"
From Testiwiki
(New page: {{variable|moderator = Virpi Kollanus}} Category: CLAIH Category: PM exposure health effects '''Boxes with dashed borders''' contain brief guidance text for completing the entri...) |
|||
| Line 28: | Line 28: | ||
'''''WHO task group (2004) <ref>[http://www.euro.who.int/document/E82792.pdf Anderson, H.R., Atkinson, R.W., Peacock, J.L., Marston, L. & Konstantinou, K. 2004. Meta-analysis of time-series studies and panel studies of Particulate Matter (PM) and Ozone (O3) - Report of a WHO task group. World Health Organization.]</ref> | '''''WHO task group (2004) <ref>[http://www.euro.who.int/document/E82792.pdf Anderson, H.R., Atkinson, R.W., Peacock, J.L., Marston, L. & Konstantinou, K. 2004. Meta-analysis of time-series studies and panel studies of Particulate Matter (PM) and Ozone (O3) - Report of a WHO task group. World Health Organization.]</ref> | ||
| − | *RR of 1.005 (95% Cl 0.981, 1.029) for bronchodilator usage by | + | *RR of 1.005 (95% Cl 0.981, 1.029) for bronchodilator usage by children with asthma (meeting PEACE study criteria) per 10 µg/m<sup>3</sup> PM<sub>10</sub> |
| − | * | + | *RR of 1.010 (95% Cl 0.990, 1.031) for bronchodilator usage by adults with asthma (well-established) per 10 µg/m<sup>3</sup> PM<sub>10</sub> |
| + | |||
| + | Note! the associations are not statistically significant at the usual 5% level. | ||
'''''CAFE CBA (2005)<ref>[http://ec.europa.eu/environment/archives/air/cafe/pdf/cba_methodology_vol2.pdf Service Contract for Carrying out Cost-Benefit Analysis of Air Quality Related Issues, in particular in the Clean Air for Europe (CAFE) Programme. Volume 2: Health Impact Assessment. AEA Technology Environment, 2005.]</ref> | '''''CAFE CBA (2005)<ref>[http://ec.europa.eu/environment/archives/air/cafe/pdf/cba_methodology_vol2.pdf Service Contract for Carrying out Cost-Benefit Analysis of Air Quality Related Issues, in particular in the Clean Air for Europe (CAFE) Programme. Volume 2: Health Impact Assessment. AEA Technology Environment, 2005.]</ref> | ||
| − | *change of 180 (95% Cl -690, 1060) days in brochodilator usage per 10 µg/m<sup>3</sup> PM<sub>10</sub> | + | *Annual change of 180 (95% Cl -690, 1060) days in brochodilator usage per 10 µg/m<sup>3</sup> PM<sub>10</sub> per 1000 children aged 5-14 years with asthma (meeting PEACE study criteria) |
| + | **Based on the RR by WHO task group (2004) and 10% background prevalence of daily bronchodilator use | ||
| + | *Annual change of 912 (95% Cl -912, 2774) days in brochodilator usage per 10 µg/m<sup>3</sup> PM<sub>10</sub> per 1000 adults aged 20+ with well-established asthma with asthma (well-established) | ||
| + | **Based on the RR by WHO task group (2004) and 50% background prevalence of daily bronchodilator use | ||
| + | **4.5% of European adult population was estimated to have well-established asthma | ||
=== Causality === | === Causality === | ||
| Line 44: | Line 50: | ||
Unit in which the result is expressed. | Unit in which the result is expressed. | ||
| − | + | Annual change in no. of days of bronchodilator usage per 10 µg/m3 increase in exposure per 1000 persons | |
=== Formula === | === Formula === | ||
| Line 60: | Line 66: | ||
! 95% Cl | ! 95% Cl | ||
|----- | |----- | ||
| − | | | + | | 5-14 |
| − | | | + | | 180 |
| − | | | + | | -690, 1060 |
| + | |----- | ||
| + | | 20+ | ||
| + | | 912 | ||
| + | | -912, 2774 | ||
| + | |} | ||
|} | |} | ||
Revision as of 12:18, 30 July 2009
This page is a variable.
The page identifier is Op_en3443 |
|---|
| Moderator:Virpi Kollanus (see all) |
|
Give your opinion to the peer rating of the content of this page. |
| Upload data
|
Boxes with dashed borders contain brief guidance text for completing the entries for new variables.
Contents
Scope
This includes a verbal definition of the spatial, temporal, and other limits (system boundaries) of the variable. The scope is defined according to the use purpose of the assessment(s) that the variable belongs to.
Exposure-response function for short-term (acute) exposure to ambient air particulate matter (PM) with an aerodynamic diameter < 10 µm and medication (bronchodilator) usage by people with asthma.
Dimensions and boundaries relevant for the variable
- Age of exposed population
- Country/other geographic area
Definition
Data
Description of the data used for obtaining the value of the variable (e.g. measurement data; mathematical method and its parameters). Please include references (preferably using the <ref></ref> tags) and links to original data, as appropriate.
WHO task group (2004) [1]
- RR of 1.005 (95% Cl 0.981, 1.029) for bronchodilator usage by children with asthma (meeting PEACE study criteria) per 10 µg/m3 PM10
- RR of 1.010 (95% Cl 0.990, 1.031) for bronchodilator usage by adults with asthma (well-established) per 10 µg/m3 PM10
Note! the associations are not statistically significant at the usual 5% level.
CAFE CBA (2005)[2]
- Annual change of 180 (95% Cl -690, 1060) days in brochodilator usage per 10 µg/m3 PM10 per 1000 children aged 5-14 years with asthma (meeting PEACE study criteria)
- Based on the RR by WHO task group (2004) and 10% background prevalence of daily bronchodilator use
- Annual change of 912 (95% Cl -912, 2774) days in brochodilator usage per 10 µg/m3 PM10 per 1000 adults aged 20+ with well-established asthma with asthma (well-established)
- Based on the RR by WHO task group (2004) and 50% background prevalence of daily bronchodilator use
- 4.5% of European adult population was estimated to have well-established asthma
Causality
List of upstream variables. The variables can be listed used descriptive (free-format) names or unambiguous identifiers (e.g. Analytica IDs).
Unit
Unit in which the result is expressed.
Annual change in no. of days of bronchodilator usage per 10 µg/m3 increase in exposure per 1000 persons
Formula
Algebra or other explicit methods if possible (e.g. Analytica code between the ''<anacode></anacode>'' delimiters).
Result
If possible, a numerical expression or distribution.
| Age group | Days | 95% Cl |
|---|---|---|
| 5-14 | 180 | -690, 1060 |
| 20+ | 912 | -912, 2774 |
|}
See also
Links to relevant information that does not belong to Definition.
References
Will appear here automatically, if cited above using the <ref></ref> tags. Additional references can also be listed here.
- ↑ Anderson, H.R., Atkinson, R.W., Peacock, J.L., Marston, L. & Konstantinou, K. 2004. Meta-analysis of time-series studies and panel studies of Particulate Matter (PM) and Ozone (O3) - Report of a WHO task group. World Health Organization.
- ↑ Service Contract for Carrying out Cost-Benefit Analysis of Air Quality Related Issues, in particular in the Clean Air for Europe (CAFE) Programme. Volume 2: Health Impact Assessment. AEA Technology Environment, 2005.
